



Cure InSight

Cure Parkinson's Autumn 2022 Newsletter

WELCOME

To the autumn edition of our newsletter.

THE LATEST

Find out how the International Linked Clinical Trials programme is shaping the Parkinson's research landscape.

THE YEAR FOR CYCLING

Read about our incredible fundraisers who have pedalled their way to raising thousands of pounds for Parkinson's research.

CHRISTMAS SHOP

If you're starting to think about Christmas, take a look at our range of festive cards and gifts.



OUR VISION

A world free from Parkinson's.

OUR MISSION

We fund and facilitate research that has the potential to cure Parkinson's. We're working with urgency to find new treatments that can slow, stop or reverse the condition.

Cover photo: Supporter Will Jensen taking part in Cure Parkinson's 2022 Raid Alpine challenge

Contents

ABOUT US

Welcome from our CEO	3
2021 Financial Summary	4
2021 Highlights	5

OUR RESEARCH

Shaping the research landscape	6
Research update	7
Accelerating clinical trials	8
Diabetes treatments for Parkinson's	9

OUR FUNDRAISING

Supporting us this Christmas	10-11
Parkinson's in the news	12-13
2022 has been the year for cycling	14
Inspired by our cycling superstars?	15
Going above and beyond with our partners	16
Cure Collective	17
Events calendar	18
Leave a legacy to Cure Parkinson's	19

Look out for QR codes dotted throughout our newsletter. To use them point your phone's camera at the QR code so you can see it on the screen. Tap on the notification that appears to open the link in your web browser and be taken to our website to find out more about our work.



VISIT OUR WEBSITE

Welcome from our CEO

Welcome to the autumn edition of Cure InSight. We are pleased to bring you the latest update on what has been a positive and exciting year so far. There is plenty more to come - it is not too late to get involved.


On first impression you might mistake this edition of Cure InSight for a cycling magazine. However, whether you frequently find yourself in a peloton, or you haven't cycled since childhood, I am confident you'll be delighted to read about how all this activity is moving us closer to a cure.

- Our friends in the Castel Office2Office cycling team, a collaboration of corporate supporters led by long-term supporter Simon Cooper, raised an astonishing £340,000 from their London-to-Amsterdam challenge.
- Our patron Mike Tindall joined five people with Parkinson's and 16 other riders to take on our extraordinary 'Raid Alpine' challenge, cycling 770km and climbing the height of Mount Everest (twice)! The Raid Alpine team raised £166,000 and were featured on BBC Breakfast.

You can read about these achievements, and others based on two wheels, on pages 11-13.

We use cycling here merely as illustrative: there are many other ways you can support the incredible efforts of our research team. Take a look at our events calendar on page 18 - there's something for everyone.

Of course, all of our fundraising efforts deliver the vital income that we need to fund the projects that we believe will lead to a cure. You can read about our financial progress on pages 3-4 and our progress shaping the Parkinson's research landscape on pages 6-9.



Pictured above: Will Cook taking part in Cure Parkinson's Raid Alpine cycle challenge

Finally, Christmas is on the horizon, at a time when everyone at the charity is very aware of the impact of the cost-of-living crisis. Our Christmas appeal may surprise you, but please take a careful look: it is written with current conditions in mind.

On behalf of the entire team at Cure Parkinson's - thank you for your support.


Will Cook, CEO, Cure Parkinson's

2021 Financial summary

Income

A second year of COVID-19 once again affected all aspects of the charity's work; but despite this income was in line with 2020.

68% (£1,656,894) of this income came from individuals who donated to, or fundraised for, the charity. 19% (£465,546) came from charitable trusts & foundations, and 12% came from our corporate partners (£294,678). 1% (£29,121) came from interest and COVID-19 government grants.




- Donations and fundraising from individuals
- Charitable trusts and foundations
- Corporate donations
- Interest and COVID-19 government grants

Expenditure

Spend on charitable activities was up 60% year on year, with research projects restarting after being delayed by COVID-19.

Investment into new research projects in 2021 totalled £1,381,007. This is an 177% increase on 2020 when £498,507 was committed to new projects.



Charitable activities:

- New research projects
- Employment and operating costs
- Research meetings

Raising funds:

- Employment and operating costs
- Fundraising activities

Cure Parkinson's 2021 Highlights

We funded **10** new research projects, a record for a single year



We launched the charity's new legacy giving programme

Planting for a Cure



We reached an audience of **1.5 million** on BBC Breakfast with our story of why a cure is so urgent



Spend on charitable activities increased by **60%** year on year to £2.1 million



A further **five drugs** were prioritised for research at the 2021 International Linked Clinical Trials committee meeting



We launched the charity's first fundraising

Development Board



Shaping the research landscape

Marking the 10th anniversary of our International Linked Clinical Trials (iLCT) initiative, Cure Parkinson's Research Officer, Rosie Fuest, discusses the importance of this vital research programme in the search for a cure.



Pictured above: Rosie Fuest, Cure Parkinson's Research Officer

At a recent meeting of representatives from the Parkinson's community, a phrase was often repeated: 'If you have met one person with Parkinson's, then you have met one person with Parkinson's.' This is a reflection on the many, complex ways in which Parkinson's can present, and pre-emptive of the fact that a cure may not be a one-size-fits-all solution. It is also one of the many reasons as to why the iLCT platform is so intrinsically important.

iLCT is now in its 10th year. This unique programme of research screens multiple new treatments with a view to identifying potentially curative treatments for Parkinson's, and its committee of world experts in Parkinson's meets just as Cure InSight goes to print. This year the committee assessed 18 drugs, many from other disease areas, but with the potential to be repurposed or repositioned to modify the progression of Parkinson's. This evaluation will identify which should be prioritised to urgently move forward into clinical trials for Parkinson's.

An array of drugs being assessed year on year means that iLCT is opening up the potential of a cure to as many people with Parkinson's as possible. Some drugs do not reach their primary endpoint or goal and whilst this is disappointing, each intervention that is trialled will result in positive learnings. Might a similar compound be more effective, might some people have responded well but others not at all and, most importantly, why?

We have however recently seen encouraging results from iLCT prioritised drugs such as anle138b and liraglutide, and we are working closely with the study teams on the critical next steps.

Over 3,000 people with Parkinson's are participating in or have taken part in iLCT prioritised drug trials alone, representing the significant impact of the programme in the Parkinson's community.


A recent publication in the Journal of Parkinson's Disease reported on all the active clinical trials currently ongoing in Parkinson's, and it is fantastic to see that nearly 40% of all drugs currently being assessed in disease-modifying trials have been evaluated in the iLCT programme.

To read this report scan the QR code below.



READ THE REPORT

Research update



Pictured above: Professor Patrik Brundin

Thank you Patrik

We would like to take this opportunity to thank Professor Patrik Brundin who has stepped down as chair of the iLCT committee after 10 years. Professor Brundin has guided the discussion of more than 250 detailed dossiers of drugs with the potential to change the progression of Parkinson's, enabling the committee to prioritise more than 45 drugs for clinical testing.

Professor Brundin is succeeded by Professor David K. Simon, of Beth Israel Deaconess Medical Center and Harvard Medical School, US, with Professor Camille Carroll, Honorary Consultant Neurologist at Plymouth Hospitals NHS Trust, as co-chair of the committee.

To read more visit our website at cureparkinsons.org.uk/new-chair-of-the-ilct-committee or use the QR code below.



READ MORE

Ambroxol update

In the spring edition of Cure InSight, we reported that following the promising results of a phase 2 trial, a drug prioritised by our iLCT committee that is widely used across Europe to treat coughs and respiratory conditions - ambroxol - is moving closer to a phase 3 clinical trial (called ASPro-PD).

Under the leadership of Professor Anthony Schapira at University College London, we anticipate that the trial will involve 330 people with Parkinson's in centres across the UK. We hope that the ASPro-PD trial will receive all due approvals and that we will be able to bring you more information on the plans for recruitment very soon. In the meantime, if you are interested in this potential trial, please consider joining the online PD Frontline study which can speed up the recruitment process to trials which might be appropriate to you.

To take part in PD Frontline visit our website at cureparkinsons.org.uk/pd-frontline or use the QR code below.



TAKE PART

To keep up-to-date with all our research news and progress, sign up to receive our monthly email newsletter on our website home page cureparkinsons.org.uk

Accelerating clinical trials

We are at a critical time for Parkinson's research. The number of people living with Parkinson's globally is growing fast; it is expected to reach over 12 million by 2040.

As well as identifying new treatments, we are focused on finding ways to speed up the assessment of each potential treatment, so as to provide the Parkinson's community with disease-modifying therapies as quickly as possible.

With that goal in mind we are key partners in a project that is reimagining Parkinson's clinical trials: The Edmond J. Safra Accelerating Clinical Treatments for Parkinson's Disease (EJS ACT-PD) initiative. Project teams made up of people from across the Parkinson's community are focused on developing a smarter, faster and more cost-effective way of testing multiple drugs in parallel. The ultimate aim is to fast-track the most promising treatments for Parkinson's, and you might be able to help...

Please join the EJS ACT-PD initiative to help develop an exciting new research trial for Parkinson's by participating in its wider patient and care partner network. Members of the network will be contacted with requests for input on a range of topics, as and when they arise. This will help the EJS ACT-PD team to gather wider perspectives from the Parkinson's community to inform decisions about research trials.

To find out more please visit our website at cureparkinsons.org.uk/find-research-studies-recruiting or use the QR code below.



JOIN EJS ACT-PD

Have your say on Parkinson's research

Recruitment and retention is a common cause for delay in clinical trial delivery. Cure Parkinson's is collaborating with Dr Emma Lane at University of Cardiff, Professor Camille Carroll at Plymouth University and a wide group of people with Parkinson's, to understand what motivates someone to participate in a trial. Our survey covers the process of taking part, from initial decision to receipt of result. It also aims to identify the impact of age, sex and other factors on trial participation.

We hope the results will inform future trial design, recruitment and communication strategies. With this aim, findings will be shared with multiple groups including the National Institute for Health and Care Research (NIHR) and the EJS ACT-PD project. The survey closes on 31 October 2022.

We encourage anyone with Parkinson's to take this opportunity to share their views and experience, regardless of whether they have participated in a clinical trial.

The survey is shaping this year's Rallying to the Challenge - our meeting designed for and by people with Parkinson's, advocates and care partners, to explore how the Parkinson's community can impact research. To find out more or to take part in the survey, please visit our website at cureparkinsons.org.uk/clinical-trial-participation-survey or use the QR code below.



FIND OUT MORE

Diabetes treatments for Parkinson's – a developing story

Research indicates there is a relationship between Parkinson's and diabetes, with some recent data suggesting treatment or prevention of diabetes may reduce the risk of Parkinson's or its progression.

Currently, one in 15 people in the UK has type 2 diabetes, and that number is increasing; the risk of developing Parkinson's in a person's lifetime is also growing. It is important to try to understand any relationship between the two conditions, and whether type-2 diabetes medications might, in turn, be able to slow the progression of Parkinson's.

The pipeline of type 2 diabetes drugs called glucagon-like peptide 1 receptor (GLP-1R) agonists being tested for Parkinson's is continuing to grow, based on compelling science. There are a number of GLP-1R agonist trials that have reported recently or will be reporting results in the near future, several of which have been supported by Cure Parkinson's.

Researchers from Cedars Sinai Hospital, Los Angeles recently presented their initial top line results of the liraglutide trial, co-funded by Van Andel Institute and Cure Parkinson's, at the American Association of Neurology annual meeting. The results indicate that liraglutide improves aspects of daily living and non-motor symptoms in people with Parkinson's.

// These results are an encouraging and critical step in our pursuit of therapies that slow or stop Parkinson's progression. We believe diabetes medications, such as liraglutide, hold particular promise and look forward to additional results from the trial.

Professor Patrik Brundin, Therapeutic Area Leader for Movement Disorders worldwide, Neuroscience and Rare Diseases, Roche, Switzerland

A large phase 2 clinical trial of another GLP-1R agonist called exenatide, showed evidence to suggest it may slow the progression of Parkinson's. This paved the way for the large phase 3 clinical trial 'Exenatide PD3 Study' that is currently underway and Cure Parkinson's is co-funding two sub-studies in this promising area of research.

In September, Cure Parkinson's with the Michael J Fox Foundation hosted a meeting to identify key areas for investigation with the researchers who are leading the projects that are exploring the potential of diabetes treatments for Parkinson's. This work will provide many additional insights about the potential of diabetes drugs as treatments for Parkinson's.

To read more about diabetes and Parkinson's please visit our website cureparkinsons.org.uk/diabetes-and-parkinsons or use the QR code below.



READ MORE

Autumn Research Update Meeting

Join us at the Royal Society of Medicine on 9 November from 2.30pm. Professor Roger Barker will provide the keynote lecture and there will be an opportunity to hear about breaking news from other Cure Parkinson's funded research. Book your place via our website at cureparkinsons.org.uk/autumn-research-update-meeting



Please do not donate to Cure Parkinson's this Christmas

(unless you can really afford to).

Each year, as Christmas approaches, charity appeals will arrive in your letterbox or email inbox; seemingly as much of a Christmas tradition as crackers, turkey or carols.

But none of us at Cure Parkinson's is in any doubt about the impact of the cost-of-living crisis that we all feel. We know many people will need to prioritise their bills, commitments and family expenditure this Christmas. As a result, our appeal is very different this year: **Please do not donate to us unless you can really afford to.**

Rest assured that we remain as committed as ever to finding a cure; we still need your money to accelerate and deliver our ground-breaking trials urgently. But we do understand the scale of the financial pressures so many are facing: those who are struggling will not be able to donate regardless of what we say here. To those, we say, feel no pressure to donate this year...

If you can support us - fantastic!

To donate, you can complete the enclosed form, order cards and gifts from our Christmas shop, or even sign up to raise funds for us this Christmas. With your support, we continue to change the face of Parkinson's research.

But if you have other priorities this year - we understand. Thank you for your past support. We know you are still behind our goal to cure Parkinson's and we hope when circumstances change you will support us once again.

Whatever your decision we wish you a very happy Christmas and a hope-filled new year.

Hope for Christmases to come

Although our appeal looks different, our mission remains the same and over the next five years, we aim to commit more therapies to trial to create new, effective treatments that affect disease progression for people with Parkinson's.

We spoke to two people living with the condition about their experience of why taking part in research gives them hope this Christmas and for future Christmases to come.



Penny's story: Supporter Penny was inspired to take part in the exenatide phase 2 clinical trial after hearing Professor Tom Foltynie speak at a Cure Parkinson's research event.


// Taking part in research has empowered me. I feel like I'm doing something to get rid of this wretched condition. I have something to offer, even if it is just to benefit my children and grandchildren. We will find a cure and I hope I'm part of it.



Rick's story: Cure Parkinson's Director of Fundraising & Marketing is taking part in the phase 3 exenatide trial.

// I can explain why I take part in research in four words - we need a cure. I'm in my second year of the exenatide drug trial. I've learnt so much from the time I've spent with research teams but, most importantly, I am contributing to the thing I want most of all: legs that work as they should, more than a few hours of sleep, good digestion - a cure!

A donation to Cure Parkinson's this Christmas will support ground-breaking research that will bring us closer to a cure that could change the lives of Penny, Rick and the 10 million people worldwide who live with Parkinson's.



HOW TO DONATE

Complete the enclosed form to donate, or order cards and gifts from our Christmas shop, and return to us using the Freepost envelope provided.

Donate online using the QR code below or by visiting donate.cureparkinsons.org.uk/christmas




Text **HOPETOCURE** followed by your donation amount to **70450**, for example:

To donate £10 text **HOPETOCURE 10**

To donate £20 text **HOPETOCURE 20**

Texts will incur the cost of your donation plus a charge at your standard network message rate; please ask bill payer's permission first. For full details please visit cureparkinsons.org.uk/about-us/our-policies.



Parkinson's in the news

Cure Parkinson's patron Mike Tindall and some of our incredible Parkinson's advocates continue to help shine a spotlight on Parkinson's.



Pictured above: Mike Tindall live on BBC Breakfast from the start of the Cure Parkinson's Raid Alpine challenge

This spring and summer, Mike Tindall has continued to help raise vital awareness of Parkinson's in the media, taking part in two interviews on BBC Breakfast.

On 11 April, World Parkinson's Day, Mike joined presenters Sally Nugent and Jon Kay on the famous red sofa to speak about the impact Parkinson's has had on his own family, and the difficulties faced by his father, Philip, who has been living with the condition for 20 years.

Mike also spoke about how research is vital to finding a cure, and mentioned the work of our International Linked Clinical Trials (iLCT) programme. Mike encouraged those wishing to get involved in research to find out more about taking part in clinical trials.

Just a few months later, Cure Parkinson's was featured on BBC Breakfast once again, as Mike spoke live to the studio from the shores of Lake Geneva. He was at the starting line of the gruelling Raid Alpine cycle challenge: he spoke of the daunting climbs he and the group were set to face over the coming week as they traversed some of the most feared Alpine roads, all to raise funds for Cure Parkinson's!

Following several cancellations due to the pandemic, Cure Parkinson's was delighted that the Raid Alpine challenge was finally able to go ahead. All at the charity were incredibly proud of the team of 22 dedicated cyclists who crossed the finish line in Nice, on Saturday 9 July, having covered an amazing 770km of distance and 18,000m of ascent.

Alongside Mike, the team of 22 included five inspirational people living with Parkinson's, Mike's Rugby World Cup-winning team-mate Iain Balshaw and Cure Parkinson's CEO Will Cook. The challenge was relentless; the ascents only increasing each day as they tackled some of the world's most famous mountain passes, including Col du Galibier, Col d'Izoard and Cime de la Bonette.

Mike's BBC Breakfast interview was accompanied by several articles in the UK national papers, as well as a number of regional pieces focusing on the team members with Parkinson's and their extraordinary achievement.

We'd like to say thank you to Alison Anderson, Claire Lehman, Simon Bland, Pete Anthem and Gary Shaughnessy for not only taking part in this immense challenge, but also working to help raise much-needed awareness of Parkinson's in the media.

We'd also like to say thank you to Mike, and to all our amazing fundraisers who have shared their stories and fundraising challenges in the media and on social media. Sharing your experiences can be a great way to shine a spotlight on Parkinson's, and the work that we are all doing to find a cure.

Nominations now open for our 2022 Fundraiser of the Year Award!

Each year, Cure Parkinson's awards 'Fundraiser of the Year' to one of our fundraisers who has really gone the extra mile, not just to raise funds but in raising awareness of Parkinson's too. Fundraisers are nominated by their friends and family and the winner is chosen by a judging panel in January.

If you know someone who has gone above and beyond to raise funds and/or awareness for Cure Parkinson's, you can nominate them by visiting our website at cureparkinsons.org.uk/nominate



2022 has been the year for cycling!

Our Raid series, featured on pages 12-13, was not the only cycling challenge to make a return following the lockdowns. Many supporters, including people with Parkinson's, took on some of the most iconic cycle routes in Europe and across the world for a cure. They cycled thousands of miles, climbed thousands of ascents and collectively raised well over half a million pounds.

Now that's some serious wheel-power!

On 27 April, the Mostyn and Postlethwaite families (pictured below) set off from Greenwich Park to tackle the 286 mile cycle to Amsterdam, raising much needed awareness and an incredible £37,320 for Cure Parkinson's along the way. Each family has been impacted by Parkinson's; Sir Nicholas Mostyn, a High Court judge, was diagnosed with the condition in 2020, and the Postlethwaite family recently lost their step-father, who had Parkinson's.

Friends Deborah O'Hare, Lucinda Osbourne, and Ali Pendle, also known as the Old Girls in Lycra raised £6,000 in June when they cycled the iconic Lands' End to John O'Groats route, whilst friends Ralph Johnson, Zac Johnson, Jeremy Maurice, and Rick McCabe raised £2,000 by cycling the Ireland End to End cycle.

It was a busy few days for cycling over the Jubilee weekend, when supporters took on Raid Local across the UK and further afield! Lidia Lonergan and son Daniel rode the hills of Dartmoor and raised an outstanding £4,500 for Cure Parkinson's.

On 3 June, the Chess Valley RFC 'Velos' – made up of team members Andy Smith, Brad Hallam, Brian Reilly, Mike Williams, Paddy Hughes, Stu Lemon, Stu Miles, and Cure Parkinson's CEO Will Cook - embarked upon a two-wheeled journey from their home ground at The Guild of Sport, Croxley Green, to the Stade Jean-Bouin, the home of Stade Francais Rugby in Paris. In celebration of the club's 25th Anniversary season, they visited 25 rugby clubs en route for a total journey of 255 miles, raising £16,550 for Cure Parkinson's, Whizz-Kids and The Matt Ratana Rugby Foundation.



Inspired by our cycling superstars?



Create your own ride

Start planning your own epic ride for 2023! Whether you're a velo fan, casual commuter, or whether you've been out of the saddle for a few years, organising your own cycle challenge is an excellent way to raise awareness and money for Cure Parkinson's. All you need to do is:

- **Plan your route.** If you need some inspiration take a look at our website for suggested UK routes as well as some creative, less conventional ride ideas.
- **Recruit your team.** You'll need friends and family around you on those ascents!
- **Start fundraising online** via the JustGiving website at [justgiving.com](https://www.justgiving.com)
- **Keep in touch** and let us know what you're up to so we can support you all the way.

To find out more or register your ride please use the QR code below or visit our website at cureparkinsons.org.uk/organise-your-own-cycle



REGISTER YOUR RIDE

Join us for Cure Parkinson's Raid Ventoux 'Club des Cinglés' Challenge

Cure Parkinson's Raid Series will be back in 2023 with our much anticipated Raid Ventoux 'Club des Cinglés' Challenge, taking place from 13-17 June 2023.

The Club des Cinglés de Mont Ventoux translates as the brotherhood of the Ventoux nutters - very apt for anyone who takes on the impressive formal challenge of cycling up the mountain three times in a day, from all directions (totalling 4443m ascent in 136km).

Riders can choose to climb the mountain up to three times. However, there is no pressure to complete the full challenge: it is more important that the challenge is at a level aspirational for you, whilst raising funds for ground-breaking clinical trials. It's going to be quite a ride!

To find out more or register your interest please use the QR code below or visit our website at cureparkinsons.org.uk/ventoux-challenge-2023



JOIN RAID VENTOUX

Going above and beyond with our partners



Pictured above: The Castel Office2Office team of riders

// The ride was a great experience and challenge for all. As well as bringing colleagues together, it engaged the wider industry and sponsors. Cure Parkinson's supported us every step of way and we're already planning our next adventure!

Simon Cooper, Head of Underwriting Insight, AEGIS London

Inspired by their friend and colleague with Parkinson's, Simon Cooper, 40 cyclists working within the Lloyd's insurance market took on a massive fundraising challenge event: to cycle over 318 miles taking on 2,588m of ascent through four countries, from the Castel offices in London to the Castel offices in Amsterdam in just three days.

This group of riders wanted to make a financial impact as ambitious as their cycling distance and set their fundraising target at £300,000. They designed their own cycling jersey for the ride, with a space for the logo of each company sponsoring them.

It didn't take long before they smashed their fundraising target and filled up the space on their jerseys. Using their connections in the insurance industry they secured sponsorship from 77 companies, many of them international.

In total an amazing £340,404 was raised; a truly fabulous example of what your company could achieve while also fundraising for Cure Parkinson's.

For more information or ideas on how you can create your own bespoke corporate fundraising event, please call Kelly on +44 (0)20 7487 3892 or email kelly@cureparkinsons.org.uk or use the QR code below.



FIND OUT MORE

Cure Collective

The Cure Collective, a special group of philanthropists choosing to make a difference to Cure Parkinson's, came together to learn more about the impact they're making.



Pictured above: Members of the Cure Collective seeing Ambriel vineyard following their research update

July 2022 saw members of the Cure Collective come together at Ambriel Vineyard to hear more about upcoming clinical trials and understand the impact of their donations, from Cure Parkinson's Deputy CEO Helen Matthews. The Cure Collective were delighted to be hosted, for this update, by Wendy and Charles Outhwaite who own and run Ambriel vineyard.

// It was an honour to host the Cure Collective. Cure Parkinson's is a charity that particularly resonates with me as both my mother and grandmother had Parkinson's before they died.

Wendy Outhwaite

Join us and play a part in making history

The Cure Collective is an opportunity to join a group united by its determination to cure Parkinson's, and supports the ground-breaking International Linked Clinical Trials (iLCT) programme.

To join, members commit to giving £5,000 or more a year for at least five years. In this way, the Cure Collective has the potential to impact the lives of the 10 million people worldwide who are living with Parkinson's.

Many members of the Cure Collective are either living with Parkinson's or have family or friends affected by the condition. The one thing all our members have in common is a desire to cure Parkinson's.

Member Benefits

Members are kept up to date with the latest developments in Parkinson's research and enjoy exclusive access to our researchers. They also come together at special events like the Ambriel vineyard tour.

To find out more about the Cure Collective, please call Grace on +44 (0)20 7487 3892 or email grace@cureparkinsons.org.uk

Events calendar

Join us at one of our many events taking place over the next six months from autumn 2022 to spring 2023.

RESEARCH EVENTS

Autumn Research Update meeting
9 November 2022

CULTURAL EVENTS

Cure³ at Bonhams
13-17 January 2023

Comedy Night at Inner Temple
March 2023

CYCLING EVENTS

Sport Parkinson's John O'Groats to
Lands End (JOGLE) ride
From 6 May 2023

Ride London-Essex 100
29 May 2023

Cure Parkinson's Raid Ventoux – The Club
des Cinglés Challenge
13–17 June 2023

RUNNING EVENTS

TCS New York Marathon
6 November 2022

London Landmarks Half Marathon
2 April 2023

TCS London Marathon
23 April 2023

ALL YEAR ROUND CHALLENGES

Skydive

£1,000 Challenge

The Ultra Challenge Series



JOIN AN EVENT

Leave a Legacy to Cure Parkinson's

By remembering Cure Parkinson's in your Will, you can help us transform the lives of millions of people around the world living with Parkinson's, now and in the future. In every new research trial, in every exciting breakthrough, your kindness will live on.

Step-by-step guide to leaving a gift to us in your Will

1. Request your free Wills guide online by visiting cureparkinsons.org.uk/leave-a-gift-in-your-will or email us at info@cureparkinsons.org.uk or write to us at:

Fundraising Team
Cure Parkinson's
120 New Cavendish Street
London W1W 6XX

2. Find a solicitor or Will writer and write or update your Will.

3. Get in touch. Please let us know if you have kindly left a gift for Cure Parkinson's in your Will.

4. Join our Planting for a Cure campaign and one of our trees will be dedicated to you or your loved one.

Pledge today and join the dozens of supporters who are committed to delivering a brighter future for people living with Parkinson's.





CURE
PARKINSON'S

Join the conversation

We'd love to tell you about what we're up to, and the most cost-effective way of doing this is by email. We promise that we will not fill your inbox with endless emails. You can change how you choose to hear from us at any time by visiting cureparkinsons.org.uk/your-permissions

You can also join us online on



120 New Cavendish Street, London W1W 6XX

amrc
ASSOCIATION OF MEDICAL RESEARCH CHARITIES



Cure Parkinson's is the operating name of The Cure Parkinson's Trust. The Cure Parkinson's Trust is a registered charity in England and Wales (1111816) and Scotland (SCO44368) and a company limited by guarantee - company number 05539974 (England and Wales).